1007877-91-9

Basic information

• Product Name: benzyl 2-(4-hydroxypiperidin-1-yl)-2-phenylacetate
• Synonyms: benzyl 2-(4-hydroxypiperidin-1-yl)-2-phenylacetate
• CAS NO: 1007877-91-9
• Molecular Weight: 0
• Mol File: 1007877-91-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: benzyl 2-(4-hydroxypiperidin-1-yl)-2-phenylacetate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 2-(4-hydroxypiperidin-1-yl)-2-phenylacetate(1007877-91-9)
• EPA Substance Registry System: benzyl 2-(4-hydroxypiperidin-1-yl)-2-phenylacetate(1007877-91-9)

Safety Data

• Hazardous Substances Data: 1007877-91-9(Hazardous Substances Data)

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 1007877-81-7 benzyl 2-phenyl-2-(tosyloxy)acetate 
• 62173-99-3 benzyl 2-hydroxy-2-phenylacetate 

Downstream Products

• 1007877-93-1 benzyl (S)-2-(4-hydroxypiperidin-1-yl)-2-phenylacetate 
• 1007877-95-3 benzyl (S)-2-(4-hydroxypiperidin-1-yl)-2-phenylacetate 

Relevant articles and documents

HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives

The isoquinolinamide series of HCV NS5A inhibitors exemplified by compounds 2b and 2c provided the first dual genotype-1a/1b (GT-1a/1b) inhibitor class that demonstrated a significant improvement in potency toward GT-1a replicons compared to that of the initial program lead, stilbene 2a. Structure-activity relationship (SAR) studies that uncovered an alternate phenylglycine-based cap series that exhibit further improvements in virology profile, along with some insights into the pharmacophoric elements associated with the GT-1a potency, are described.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.